Invention Grant
- Patent Title: Pyrimidine compound as JAK kinase inhibitor
-
Application No.: US16390175Application Date: 2019-04-22
-
Publication No.: US10562894B2Publication Date: 2020-02-18
- Inventor: Jennifer Kozak , Ryan Hudson , Gary E. L. Brandt , Robert Murray McKinnell
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Florence Jovic
- Main IPC: C07D451/14
- IPC: C07D451/14 ; A61K9/06 ; A61K9/00 ; A61P17/00 ; A61P37/06 ; A61K31/506 ; C07D451/04 ; A61K45/06 ; C07D403/12 ; A61P17/14

Abstract:
The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
Public/Granted literature
- US20190241555A1 PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR Public/Granted day:2019-08-08
Information query